Page last updated: 2024-11-12

1,4,6,8-tetramethyl-2h-furo(2,3-h)quinolin-2-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,4,6,8-tetramethyl-2H-furo(2,3-h)quinolin-2-one: a tetramethylfuroquinolinone; an isoster of angelicin; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10466871
CHEMBL ID24556
SCHEMBL ID6140019
MeSH IDM0267109

Synonyms (8)

Synonym
174022-38-9
1,4,6,8-tetramethyl-2h-furo(2,3-h)quinolin-2-one
CHEMBL24556
SCHEMBL6140019
1,4,6,8-tetramethylfuro[2,3-h]quinolin-2(1h)-one
1,4,6,8-tetramethyl-2h-furo[2,3-h]quinolin-2-one
DTXSID20877776
1,4,6,8-tetramethylfuro[2,3-h]quinolin-2-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID66155Compound was tested for the inhibition of DNA synthesis in Ehrlich cells by incubation in the dark.1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID16673Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID21302Solubility of compound in water1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID66159Compound was tested for the inhibition of DNA synthesis in Ehrlich cells by incubation in the dark relative to furoquinolinone1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID66161Compound was tested for the inhibition of RNA synthesis in Ehrlich cells by incubation in the dark relative to furoquinolinone1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID66156Compound was tested for the inhibition of RNA synthesis in Ehrlich cells by incubation in the dark.1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID66153Compound was tested for the inhibition of RNA synthesis in Ehrlich cells by UV -A Irradiation1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID66152Compound was tested for the inhibition of DNA synthesis in Ehrlich cells by UV -A Irradiation1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID66160Compound was tested for the inhibition of RNA synthesis in Ehrlich cells by UV -A Irradiation relative to furoquinolinone1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID21075Partition Coefficient in n-octanol / water medium1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID66158Compound was tested for the inhibition of DNA synthesis in Ehrlich cells by UV -A Irradiation relative to furoquinolinone1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID208392Surviving fraction was evaluated at concentration 2 uM in T2 phage1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]